Forgot to take your pill or did your condom break? For situations like these, there is the “morning-after pill”. A tool that emerged from a research project at the University of Basel is designed to make conversations between pharmacy staff and customers as comfortable as possible and help them make the best possible decision.
A new EU strategy is placing greater emphasis on artificial intelligence in the management of heart disease. Legal researcher Hannah van Kolfschooten believes this is premature. Among other things, she criticizes the fact that no concrete benefit for patients has yet been demonstrated and that there are gaps in the legislation.
Researchers at the University of Basel and the Technical University of Munich have developed a new method to reveal the collective motion of electrons in one of the most elusive states of matter: the Wigner crystal.
Sindi-Leigh McBride investigates the work of making a living, making a life, and where the two intersect in changing climates, looking to novels and films for visions of the future in a world undergoing profound change.
A patient with mysterious symptoms refuses to give up: he wants to know what’s wrong. But no known diagnosis seems to fit. Professor Mike Recher explains how his team finally found the cause of the symptoms, and why a whole new field of immune disorders is emerging.
Transport incurs costs that are largely invisible today. A study by the University of Basel shows how these external costs could be charged for and the revenue redistributed in a socially acceptable way.
Botany professor Ansgar Kahmen has been studying Switzerland’s forests for years. There has never been a summer as hot and dry as that of 2026 since records began. It is already clear that the forests of northwestern Switzerland are suffering severe damage. The forest of the future will look much different from today, the biologist is convinced.
Beauty is in the eye of the beholder. But how far does the freedom to alter one’s own body extend? The legal scholar Nuran Haydar Celik examines the limits the law is allowed to impose on interventions lacking medical indications.
Modern therapies have transformed care for people with multiple sclerosis (MS). Yet the disease continues to progress in some patients, even in the absence of relapses. Detecting and treating this gradual worsening of disability remains one of the greatest challenges in MS care. Researchers now report on a blood marker that could help track disease progression and monitor treatment response.
